KLOW is a blend name for GHK-Cu + TB-500 + BPC-157 + KPV. It has no single molecular identity; each component has its own reference and evidence record.
Published by Elevated Pharma ·
Research BlendsComponent sources only
Identity
What is KLOW?
A named combination of 4 separately defined components: GHK-Cu + TB-500 + BPC-157 + KPV.
Research context
What has KLOW been studied for?
No study of this exact combination was found. Read each component’s key studies separately.
Evidence boundary
What does the research not show?
Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
U.S. status · November 7, 2026
Is KLOW FDA-approved?
FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine. It is widely studied in skin and wound models and used in topical cosmetics.
U.S. status
FDA removed injectable GHK-Cu from its Category 2 compounding list in April 2026 and scheduled it for advisory-committee review before the end of February 2027. It is not covered by the October 2026 HHS interim policy.
FDA defines TB-500 as the seven-residue thymosin beta-4 fragment LKKTETQ with N-terminal acetylation. It is not full-length thymosin beta-4, and most published research is on the full-length protein.
U.S. status
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; the nominated substance was t…
BPC-157 is a synthetic 15-residue peptide studied mostly in rodent models of tissue and gut injury. In 2026 it moved from FDA’s restricted list to an HHS interim compounding policy, though it remains unapproved.
U.S. status
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; nominated for ulcerative coli…
KPV is the tripeptide lysine-proline-valine, the C-terminal end of alpha-MSH. It is studied in cell and mouse models of inflammation, especially colitis.
U.S. status
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention). On October 28, 2026, HHS iss…
Reference identifiers
KLOW identity data
Database identity describes the reference substance, not any specific material or lot.